Aptamer Articles & Analysis
17 news found
Oligonucleotide Manufacturing BOC Sciences is a leading manufacturer of high-quality oligonucleotide products, including ASOs, siRNAs, aptamers, cap analogs, CpG ODNs, and microRNAs. Its oligonucleotides are widely used in research, diagnostics, and therapeutics, and are available in various sizes, purities, and modifications to suit different applications. XDC Bioconjugation ...
BOC Sciences' exosome delivery systems are engineered to deal with every type of nucleic acid, with the following conventional nucleic acid types now available: siRNA, mRNA, miRNA, circRNA, lncRNA, DNA, Aptamer, ASO, etc. If there are any specific or unique requirements, BOC Sciences has a professional technical team to provide swift and tailored solutions. ...
These chemicals have inclusive applications in mRNA vaccines and therapeutics, RNA therapeutics (ASO, siRNA, miRNA, Aptamer), nucleic acid detection, gene sequencing and editing (CRISPR-Cas9), and oligonucleotide synthesis, etc. ...
CD Genomics is a world-leading genomics services company, innovating in sequencing services for the genomics industry as well as genotyping, library construction, bioinformatics, aptamers, microarrays, health diagnostics, mutagenesis analysis, and more. ...
The claims cover a proprietary method of loading exosomes with nucleic acids via binding to nucleic acid binding proteins PUF, Cas6, Cas13 or a nucleic acid aptamer binding protein, and they reinforce the Company’s leading position within field of exosome therapeutics. ...
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Qualigen’s aptamer platform, of which QN-247 is the lead candidate, inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells, thus influencing their proliferation, ...
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Qualigen’s aptamer platform, of which QN-247 is the lead candidate, inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells, thus influencing their proliferation, ...
Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses. ...
It is often used in targeted drug delivery with the lipid bilayer to improve drug solubility, the PEG to provide stealth property, extend circulation half-life and reduce non-specific protein binding or cell adhesion, and the reactive maleimide to bioconjugate targeting molecules including antibody, aptamer, protein, and peptide. DSPE PEG maleimide is one of Creative Enzymes ...
In addition to this neutralizing antibody development, Creative Biolabs’ antiviral drug discovery services also cover inhibitors of host cell protease (darunavir and lopinavir for SARS-CoV-2), viral protease inhibitors, nucleoside analogue inhibitors, RNA synthesis inhibitors, antiviral peptide, broad-spectrum antiviral drugs, anti-inflammatory drugs, aptamers, complement ...
AptaMatrix, Inc., a Syracuse-based biotech company focused on developing aptamer-based technologies for diagnostic applications, announces that it has been awarded a $2M Phase II Small Business Innovation Research (SBIR) grant by the National Institute of General Medical Sciences (NIGMS) institute of the National Institutes of Health (NIH). The Phase II award will allow ...
About 2bind 2bind GmbH was founded in Regensburg in 2011 and provides tailor-made biophysics services and solutions that are perfectly adjusted to precise needs in key, high-value areas of Drug Discovery, Antibody Research, Aptamer Characterization, and Protein Biophysics. A state-of-the-art portfolio of biophysical technologies enables them to provide a complete and ...
During this webinar, you will learn how the combination of the X-Aptamer Selection Kit from AM Biotechnologies with HORIBA's SPRi system allows you to develop and screen aptamers from small molecules in a short period of time. ...
During this webinar, you will learn how the combination of the X-Aptamer Selection Kit from AM Biotechnologies with HORIBA's SPRi system allows you to develop and screen aptamers from small molecules in a short period of time. ...
In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular science. Register ...
In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular science. Register ...
In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular science. Register ...